HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Patrizio Giacomini Selected Research

Breast Neoplasms (Breast Cancer)

1/2022Unusual phylogenetic tree and circulating actionable ESR1 mutations in an aggressive luminal/HER2-low breast cancer: Case report.
11/2021Liquid biopsy identifies actionable dynamic predictors of resistance to Trastuzumab Emtansine (T-DM1) in advanced HER2-positive breast cancer.
1/2021TOOLBOX: Strep‑Tagged nano‑assemblies of antibody‑drug‑conjugates (ADC) for modular and conditional cancer drugging
8/2017Bloch Surface Waves Biosensors for High Sensitivity Detection of Soluble ERBB2 in a Complex Biological Environment.
6/2017Detection of soluble ERBB2 in breast cancer cell lysates using a combined label-free/fluorescence platform based on Bloch surface waves.
12/2013Antibody-drug conjugates: targeting melanoma with cisplatin encapsulated in protein-cage nanoparticles based on human ferritin.
9/2006Functional expression of a single-chain antibody to ErbB-2 in plants and cell-free systems.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Patrizio Giacomini Research Topics

Disease

32Neoplasms (Cancer)
01/2024 - 07/2003
9Melanoma (Melanoma, Malignant)
02/2023 - 04/2006
7Breast Neoplasms (Breast Cancer)
01/2022 - 09/2006
5Carcinoma (Carcinomatosis)
10/2015 - 04/2006
4Colorectal Neoplasms (Colorectal Cancer)
12/2020 - 06/2018
3Neuroblastoma
01/2012 - 05/2008
2Circulating Neoplastic Cells
02/2023 - 08/2020
2Lymphoma (Lymphomas)
03/2011 - 04/2006
1Clinical Deterioration
10/2023
1Sarcoma (Soft Tissue Sarcoma)
08/2020
1Ewing Sarcoma (Sarcoma, Ewing)
01/2018
1T-Cell Lymphoma (Lymphoma, T Cell)
03/2011
1Carcinogenesis
05/2008
1Nevus (Nevi)
06/2006
1Leukemia
04/2006

Drug/Important Bio-Agent (IBA)

5Peptides (Polypeptides)IBA
01/2024 - 04/2006
5Ferritins (Ferritin)IBA
10/2023 - 12/2013
5MicroRNAs (MicroRNA)IBA
02/2023 - 05/2008
5LigandsIBA
10/2015 - 09/2011
4DNA (Deoxyribonucleic Acid)IBA
10/2023 - 10/2018
4Circulating Tumor DNAIBA
10/2023 - 06/2018
4HLA Antigens (Human Leukocyte Antigens)IBA
01/2014 - 07/2003
4AminopeptidasesIBA
01/2012 - 04/2006
3Cell-Free Nucleic AcidsIBA
01/2021 - 10/2018
3Biomarkers (Surrogate Marker)IBA
12/2020 - 06/2017
3Proteins (Proteins, Gene)FDA Link
08/2017 - 12/2013
3HLA-A Antigens (HLA-A)IBA
01/2014 - 01/2007
2Drug CarriersIBA
10/2023 - 02/2021
2Topoisomerase I InhibitorsIBA
10/2023 - 02/2021
2Genz-644282IBA
10/2023 - 02/2021
2Peptide Hydrolases (Proteases)FDA Link
02/2021 - 04/2006
2Immunoglobulin FragmentsIBA
01/2021 - 11/2005
2ErbB Receptors (EGF Receptor)IBA
12/2020 - 09/2006
2HLA-B Antigens (HLA-B)IBA
01/2014 - 01/2007
2HLA-C Antigens (HLA-C)IBA
01/2014 - 01/2007
2Monoclonal AntibodiesIBA
12/2013 - 01/2007
2NF-kappa B (NF-kB)IBA
01/2012 - 02/2010
2ParaffinIBA
10/2011 - 01/2007
2Formaldehyde (Formol)FDA Link
10/2011 - 01/2007
1Tumor Biomarkers (Tumor Markers)IBA
02/2023
1Phenobarbital (Luminal)FDA Link
01/2022
1Hormones (Hormone)IBA
01/2022
1Ado-Trastuzumab EmtansineIBA
11/2021
1ferritin receptorIBA
02/2021
1Peptide Nucleic AcidsIBA
01/2021
1ProdrugsIBA
01/2021
1EWS-FLI fusion proteinIBA
01/2018
1Matrix Metalloproteinases (MMPs)IBA
10/2016
1Doxorubicin (Adriamycin)FDA LinkGeneric
10/2016
1ApoferritinsIBA
10/2016
1VitaminsIBA
10/2015
1Ascorbic Acid (Vitamin C)FDA LinkGeneric
10/2015
1Succinic Acid (Succinate)IBA
10/2015
1Vitamin K 3 (Menadione)FDA Link
10/2015
1NK Cell Lectin-Like Receptor Subfamily KIBA
10/2015
1micaIBA
10/2015
1Reactive Oxygen Species (Oxygen Radicals)IBA
10/2015
1HLA-G Antigens (HLA G)IBA
01/2014
1Cisplatin (Platino)FDA LinkGeneric
12/2013
1ThymidineIBA
12/2013
1AntigensIBA
12/2013
1Immunoconjugates (Immunoconjugate)IBA
12/2013
1Antiviral Agents (Antivirals)IBA
10/2013
1Fluorescent Dyes (Fluorescent Probes)IBA
10/2013
11-(2-(dodecyloxy)ethyl)pyrrolidine hydrochloride (DEP)IBA
10/2013
1fluorexon (calcein)IBA
10/2013
1Immunosuppressive Agents (Immunosuppressants)IBA
02/2013
1Dinoprostone (PGE2)FDA Link
02/2013
1Antineoplastic Agents (Antineoplastics)IBA
02/2013
1Indoleamine-Pyrrole 2,3,-Dioxygenase (Indoleamine 2,3 Dioxygenase)IBA
02/2013
1Neoplasm Antigens (Tumor Antigens)IBA
01/2012
1NK Cell Lectin-Like Receptor Subfamily CIBA
10/2011
1Histocompatibility Antigens Class IIBA
03/2011
1EpitopesIBA
03/2009
1HLA-A2 Antigen (HLA A2 Antigen)IBA
03/2009
13' Untranslated Regions (3' UTR)IBA
05/2008
1Messenger RNA (mRNA)IBA
05/2008
1AntagomirsIBA
05/2008
1Coloring Agents (Dyes)IBA
01/2007
1Epidermal Growth Factor (EGF)IBA
09/2006
1AntibodiesIBA
09/2006
1TetraspaninsIBA
06/2006
1Collagen Type VIIBA
06/2006
1Complementary DNA (cDNA)IBA
06/2006

Therapy/Procedure

12Therapeutics
10/2023 - 11/2005
3Precision Medicine
02/2023 - 08/2020
3Immunotherapy
04/2021 - 03/2009
1Neoadjuvant Therapy
01/2018
1Chemoprevention
10/2015
1Combination Drug Therapy (Combination Chemotherapy)
12/2013
1Intravenous Administration
12/2013
1Bioreactors (Bioreactor)
09/2006